Marco Salvatore


Marco Salvatore is currently professor of Diagnostic Imaging and Director of the Dept. of Biomorphological and Functional Studies of the University “Federico II” of Naples.

• From 1989 to 1995 he was Scientific Director of the National Tumor Institute (Naples).
• From 1992, President of the Italian Committee for ‘Europe against Cancer’.
• From 1993, member of the National Oncological Commission of the Health Ministry.
• From 1994 to 1997 he served on the CNR Committee for clinical applications in oncological research.
• From 1995 to 1999 he directed the CNRCenter for the Study of Nuclear Medicine (Naples). From 1996 to 1998 he was President of the Health Ministry’s Commission on Imaging Diagnostics.
• He is a member of the Scientific Committee of the European Institute of Oncology (Milan).
• From 1998 he is President of the University Diploma Course for Technicians of Medical Radiology of the University of Naples ‘Federico II’.
• From 1999 he is a member of the Directive Council of the CNR.
• From 1999 member of the Organizative Committee of the Scuola Motoria dell’Istituto Navale di Napoli.
• From 1999 member of the Executive Committee of the European Association of Nuclear Medicine.
• From 2000 National Delegate to the European Medical Research Council.
• He is author of more than 250 scientific articles indexed in Medline.

Selected Publications

• Del Vecchio S, Ciarmiello A, Pace L, Potena MI, Carriero MV, Mainolfi C, Thomas R, D'Aiuto G, Tsuruo T, Salvatore M. Fractional retention of 99mTc-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients. J Nucl Med 1997;38:1348-1351
• Del Vecchio S, Ciarmiello A, Potena MI, Carriero MV, Mainolfi C, Botti G, Thomas R, Cerra M, D'Aiuto G, Tsuruo T, Salvatore M. In vivo detection of multidrug-resistant (MDR1) phenotype by 99mTc-Sestamibi scan in untreated breast cancer patients. Eur J Nucl Med 1997;24:150-159, 1997
• Ciarmiello A, Del Vecchio S, Silvestro P, Potena MI, Carriero MV, Thomas R, Botti G, D'Aiuto G, Salvatore M. Tumor clearance of Technetium 99m-Sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 1998;16:1677-1683
• Carriero MV, Del Vecchio S, Capozzoli M, Franco P, Fontana L, Zannetti A, Botti G, D'Aiuto G, Salvatore M, Stoppelli MP. Urokinase receptor interacts with alpha(v)beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer. Cancer Res 1999;595307-5314
• Zannetti A, Del Vecchio S, Carriero MV, Fonti R, Franco P, Botti G, D'Aiuto G, Stoppelli MP, Salvatore M. Coordinate up-regulation of Sp1 DNA binding activity and urokinase receptor expression in breast carcinoma.; Cancer Res 2000;60:1546-1511
• Imbriaco M, Megibow AJ, Camera L, Pace L, Mainenti PP, Romano M, Selva G, Salvatore M. Dual-phase versus single-phase helical CT to detect and assess resectability of pancreatic carcinoma. AJR Am J Roentgenol. 2002 Jun; 178(6): 1473-9.
  
• Del Vecchio S, Zannetti A, Aloj L, Caraco C, Ciarmiello A, Salvatore M. Inhibition of early 99mTc-MIBI uptake by Bcl-2 anti-apoptotic protein overexpression in untreated breast carcinoma. Eur J Nucl Med Mol Imaging. 2003 Jun; 30(6): 879-87. Epub 2003 Apr 30.